BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Lee HY, Oh H, Park CH, Yeo YH, Nguyen MH, Jun DW. Comparison of renal safety of tenofovir and entecavir in patients with chronic hepatitis B: Systematic review with meta-analysis. World J Gastroenterol 2019; 25(23): 2961-2972 [PMID: 31249453 DOI: 10.3748/wjg.v25.i23.2961]
URL: https://www.wjgnet.com/1948-5182/full/v25/i23/2961.htm
Number Citing Articles
1
HeeKyoung Choi, Gi Hyeon Seo. Entecavir versus Tenofovir for the Prevention of Hepatocellular Carcinoma in Treatment-naïve Chronic Hepatitis B Patients in KoreaJournal of Korean Medical Science 2021; 36(14) doi: 10.3346/jkms.2021.36.e89
2
Xiaoxian Yang, Haiyi Yan, Xiuju Zhang, Xueying Qin, Peng Guo. Comparison of renal safety and bone mineral density of tenofovir and entecavir in patients with chronic hepatitis B: a systematic review and meta-analysisInternational Journal of Infectious Diseases 2022; 124: 133 doi: 10.1016/j.ijid.2022.09.021
3
Jin Shang, Huan Liu, Qin Wen, Rili M ise, You Tu, Lang Bai, Hong Tang. Analysis of long-term safety and efficacy of nucleos(t)ide analogue therapy for chronic hepatitis B throughout pregnancyInternational Journal of Infectious Diseases 2021; 105: 626 doi: 10.1016/j.ijid.2021.03.023
4
Ramesh Kumar, Rajeev Nayan Priyadarshi, Utpal Anand. Chronic renal dysfunction in cirrhosis: A new frontier in hepatologyWorld Journal of Gastroenterology 2021; 27(11): 990-1005 doi: 10.3748/wjg.v27.i11.990
5
Gezahegn M Woldemedihn, Hanna Aberra, Hailemichael Desalegn, Nega Berhe, Denekew Bitew Belay, Corina S Rueegg, Asgeir Johannessen. Renal Safety of Long-term Tenofovir Disoproxil Fumarate Treatment in Patients With Chronic Hepatitis BOpen Forum Infectious Diseases 2023; 10(8) doi: 10.1093/ofid/ofad404
6
Norio Itokawa, Masanori Atsukawa, Akihito Tsubota, Koichi Takaguchi, Makoto Nakamuta, Atsushi Hiraoka, Keizo Kato, Hiroshi Abe, Shigeru Mikami, Noritomo Shimada, Makoto Chuma, Akito Nozaki, Haruki Uojima, Chikara Ogawa, Toru Asano, Joji Tani, Asahiro Morishita, Tomonori Senoh, Naoki Yamashita, Tsunekazu Oikawa, Yoshihiro Matsumoto, Mai Koeda, Yuji Yoshida, Tomohide Tanabe, Tomomi Okubo, Taeang Arai, Korenobu Hayama, Ai‐Nakagawa Iwashita, Chisa Kondo, Toshifumi Tada, Hidenori Toyoda, Takashi Kumada, Katsuhiko Iwakiri. Sequential therapy from entecavir to tenofovir alafenamide versus continuous entecavir monotherapy for patients with chronic hepatitis BJGH Open 2021; 5(1): 34 doi: 10.1002/jgh3.12443
7
Kun Li, Yadong Cui, Xue Zheng, Chunyan Min, Jian Zhang, Zhanpeng Yan, Yu Ji, Fei Ge, Hualiang Ji, Fangshi Zhu. Jian Gan powder ameliorates immunological liver injury in mice by modulating the gut microbiota and metabolic profilesEuropean Journal of Medical Research 2024; 29(1) doi: 10.1186/s40001-024-01827-2
8
Lung-Yi Mak, Joseph Hoang, Dae Won Jun, Chien-Hung Chen, Cheng-Yuan Peng, Ming-Lun Yeh, Sung Eun Kim, Daniel Q. Huang, Jae Yoon Jeong, Eileen Yoon, Hyunwoo Oh, Pei-Chien Tsai, Chung-Feng Huang, Sang Bong Ahn, Huy Trinh, Qing Xie, Grace L. H. Wong, Masaru Enomoto, Jae-Jun Shim, Dong-Hyun Lee, Li Liu, Ritsuzo Kozuka, Yong Kyun Cho, Soung Won Jeong, Hyoung Su Kim, Lindsey Trinh, Allen Dao, Rui Huang, Rex Wan-Hin Hui, Vivien Tsui, Sabrina Quek, Htet Htet toe Wai Khine, Eiichi Ogawa, Chia Yen Dai, Jee Fu Huang, Ramsey Cheung, Chao Wu, Wan-Long Chuang, Seng Gee Lim, Ming-Lung Yu, Man-Fung Yuen, Mindie H. Nguyen. Longitudinal renal changes in chronic hepatitis B patients treated with entecavir versus TDF: a REAL-B studyHepatology International 2022; 16(1): 48 doi: 10.1007/s12072-021-10271-x